Impact of the Gut Microbiome on Skin Fibrosis: a Mendelian Randomization Study
Overview
Authors
Affiliations
Objective: Skin fibrosis is a lesion in the dermis causing to itching, pain, and psychological stress. The gut microbiome plays as an essential role in skin diseases developments. We conducted a Mendelian randomization study to determine the causal association between the gut microbiome and skin fibrosis.
Methods: We retrieved valid instrumental variables from the genome-wide association study (GWAS) files of the gut microbiome ( = 18,340) conducted by the MiBioGen consortium. Skin fibrosis-associated data were downloaded from the GWAS Catalog. Subsequently, a two-sample Mendelian randomization (MR) analysis was performed to determine whether the gut microbiome was related to skin fibrosis. A reverse MR analysis was also performed on the bacterial traits which were causally associated with skin fibrosis in the forward MR analysis. In addition, we performed an MR-Pleiotropy Residual Sum and Outlier analysis to remove outliers and a sensitivity analysis to verify our results.
Results: According to the inverse variance-weighted estimation, we identified that ten bacterial traits (, , , , , , , and ) were negatively correlated with skin fibrosis while five bacterial traits (, , , ), and ) were positively correlated. No results were obtained from reverse MR analysis. No significant heterogeneity or horizontal pleiotropy was observed in MR analysis.
Objective Conclusion: There is a causal association between the gut microbiome and skin fibrosis, indicating the existence of a gut-skin axis. This provides a new breakthrough point for mechanistic and clinical studies of skin fibrosis.
The gut-skin axis: a bi-directional, microbiota-driven relationship with therapeutic potential.
Jimenez-Sanchez M, Celiberto L, Yang H, Sham H, Vallance B Gut Microbes. 2025; 17(1):2473524.
PMID: 40050613 PMC: 11901370. DOI: 10.1080/19490976.2025.2473524.
Skin Microbiota, Immune Cell, and Skin Fibrosis: A Comprehensive Mendelian Randomization Study.
Zhao Z, Rong Y, Yin R, Zeng R, Xu Z, Lv D Biomedicines. 2024; 12(10).
PMID: 39457721 PMC: 11505207. DOI: 10.3390/biomedicines12102409.